Monomer Bio is a technology company.
Monomer Bio has raised $6.0M across 1 funding round.
Monomer Bio has raised $6.0M in total across 1 funding round.
Monomer Bio is a San Francisco Bay Area-based technology company that develops an AI-powered laboratory automation platform specializing in cell culture workflows for biotech research. Founded in 2021 and headquartered in Pacifica, California, it integrates standard lab hardware—like incubators, liquid handlers, and imagers—with software for automation, real-time monitoring, data analysis, and machine learning to streamline complex cell-based experiments.[1][2][3][4] The platform serves biology researchers, biotech startups, and institutions working on cell and gene therapies, iPSC-derived organoids, stem cell differentiation, cell engineering, and medical implants, solving the bottleneck of manual processes that limit scalability and discovery speed.[1][2][3][4] With $5.6 million in seed funding, Monomer Bio enables scientists to automate protocols, track cell health, generate insights from vast datasets, and focus on innovation rather than routine tasks, accelerating drug and therapy development.[1][2]
Monomer Bio was founded in 2021 by CEO and co-founder Jimmy Sastra, alongside a team passionate about bridging automation and AI in biotech labs.[1][3] The idea emerged from recognizing the "critical bottleneck" of manual cell culture processes in fast-growing fields like cell and gene therapy, where disparate hardware and software hinder scalability.[1][3] Early traction came from partnerships, such as with Indee Labs in December 2022 to automate Hydropore™ workflows for engineered immune cells, and implementations for customers ranging from startups to research institutions automating cell culture workcells.[2][3] This seed-stage company quickly raised $5.6 million, including from investors like Talis Capital, validating its approach to redefining lab research as an integrated "operating system" for biotechnology.[1][2][5]
Monomer Bio rides the explosion in cell and gene therapy, where demand for scalable, data-rich experiments outpaces manual lab capabilities amid a biotech funding resurgence post-2022 downturns.[1][3] Timing is ideal: AI advancements enable predictive analytics on cell data, while hardware commoditization lowers automation barriers, aligning with trends in synthetic biology and personalized medicine.[1][3][5] Market forces like rising R&D costs and talent shortages favor software overlays like Monomer's, which boost efficiency for cash-strapped startups and institutions.[2][4] By standardizing workflows and enabling ML apps, it influences the ecosystem—democratizing automation, fostering third-party algorithms, and accelerating breakthroughs in therapies and implants, much like cloud platforms transformed software dev.[3]
Monomer Bio is poised to dominate as the "operating system for biotechnology research," expanding from cell culture to full cell engineering pipelines with in-house and third-party ML tools.[3] Next steps include broader hardware integrations, more partnerships like Indee Labs, and scaling to "any biologist" via plug-and-play automation amid AI-biotech convergence.[2][3][4] Trends like multi-omics data explosion and automated screening will propel growth, potentially evolving Monomer into a platform leader influencing how therapies reach patients faster. This seed-funded innovator, smashing manual bottlenecks, positions biotech for a systematically designed future.[1][3]
Monomer Bio has raised $6.0M in total across 1 funding round.
Monomer Bio's investors include Addition, Alchemist Accelerator, Amino Collective, backtrace capital, BoxOne Ventures, SNR, Talis Capital, Steve King, Tayo Oviosu.
Monomer Bio has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $6.0M Seed | Addition, Alchemist Accelerator, Amino Collective, backtrace capital, BoxOne Ventures, SNR, Talis Capital, Steve King, Tayo Oviosu |